BRPI0517742A - method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual - Google Patents

method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual

Info

Publication number
BRPI0517742A
BRPI0517742A BRPI0517742-1A BRPI0517742A BRPI0517742A BR PI0517742 A BRPI0517742 A BR PI0517742A BR PI0517742 A BRPI0517742 A BR PI0517742A BR PI0517742 A BRPI0517742 A BR PI0517742A
Authority
BR
Brazil
Prior art keywords
influenza virus
individual
particle
cell
nucleic acid
Prior art date
Application number
BRPI0517742-1A
Other languages
Portuguese (pt)
Inventor
Wit Emmie De
Monique I J Spronken
Ron A M Fouchier
Albert D M E Osterhaus
Original Assignee
Solvay Pharm Bv
Univ Erasmus Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Univ Erasmus Medical Ct filed Critical Solvay Pharm Bv
Priority claimed from PCT/EP2005/055808 external-priority patent/WO2006051069A2/en
Publication of BRPI0517742A publication Critical patent/BRPI0517742A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO PARA OBTER UMA PARTìCULA DO VìRUS DA INFLUENZA CONDICIONALMENTE DEFEITUOSA, PARTìCULA DE VìRUS DA INFLUENZA, CéLULA, COMPOSIçãO, USO DA MESMA, MéTODO PARA GERAR PROTEçãO IMUNOLóGICA CONTRA INFECçãO DE UM INDIVìDUO COM UM VìRUS DA INFLUENZA, USO DE UMA PARTìCULA, E, MéTODOS PARA SUPRIR UM áCIDO NUCLEICO QUE NãO CODIFICA UM PEPTìDEO DA INFLUENZA, A UMA CéLULA E A UM INDIVìDUO. A invenção refere-se ao campo do vírus da e da vacinação contra a influenza. A invenção fornece uma partícula do vírus da influenza condicionalmente defeituosa, tendo sete diferentes segmentos de ácido nucleico. A invenção também fornece uma partícula do vírus da influenza condicionalmente defeituosa, faltando-lhe um segmento de ácido nucleico do vírus da influenza, selecionado do grupo de segmentos essencialmente codificando a polimerase acídica (PA), a polimerase básica 1 (PB1) e a polimerase básica 2 (PB2). Em particular, a invenção fornece partículas do vírus da influenza defeituosas, tendo sete diferentes segmentos de ácido nucleico do vírus da influenza e faltando-lhes um segmento do ácido nucleico do vírus da influenza, essencialmente codificando a polimerase acídica. Além disso, a invenção provê o uso de uma composição compreendendo uma partícula do vírus da influenza defeituoso de acordo com a invenção, para a produção de uma composição farmacêutica direcionada à geração de proteção imunológica contra infecção de um indivíduo com um vírus da influenza e fornece um método para gerar proteção imunológica contra infecção de um individuo com um vírus da influenza, compreendendo prover um individuo em necessidade com uma composição compreendendo tal partícula de vírus da influenza defeituosa.METHOD FOR OBTAINING A CONDITIONALLY DEFECTIVE INFLUENUS VIRUS PARTICLE, INFLUENCE VIRUS PARTICLE, CELL, COMPOSITION, USE OF THE SAME, METHOD FOR GENERATING IMMUNE INFUSTIC PROTECTION WITH INFLUENOUS INFUSION TO SUPPLY NUCLEIC ACID THAT DOESN'T CODE A PEPTIDE OF INFLUENCE, A CELL AND AN INDIVIDUAL. The invention relates to the field of influenza vaccination and virus. The invention provides a conditionally defective influenza virus particle having seven different nucleic acid segments. The invention also provides a conditionally defective influenza virus particle, lacking an influenza virus nucleic acid segment selected from the group of segments essentially encoding acidic polymerase (PA), basic polymerase 1 (PB1) and polymerase basic 2 (PB2). In particular, the invention provides defective influenza virus particles having seven different influenza virus nucleic acid segments and lacking one influenza virus nucleic acid segment, essentially encoding the acidic polymerase. In addition, the invention provides the use of a composition comprising a defective influenza virus particle according to the invention for the production of a pharmaceutical composition directed to the generation of immunological protection against infection of an individual with an influenza virus and provides A method for generating immunological protection against infection of an individual with an influenza virus, comprising providing an individual in need with a composition comprising such a defective influenza virus particle.

BRPI0517742-1A 2004-11-11 2005-11-08 method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual BRPI0517742A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04105696 2004-11-11
EP05105708 2005-06-27
PCT/EP2005/055808 WO2006051069A2 (en) 2004-11-11 2005-11-08 Defective influenza virus particles

Publications (1)

Publication Number Publication Date
BRPI0517742A true BRPI0517742A (en) 2008-10-21

Family

ID=39869799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517742-1A BRPI0517742A (en) 2004-11-11 2005-11-08 method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual

Country Status (3)

Country Link
CN (1) CN102586199A (en)
BR (1) BRPI0517742A (en)
TW (1) TW200621286A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201310031D0 (en) * 2013-06-05 2013-07-17 Pirbright Inst The Cell
EP3063273B8 (en) * 2013-10-28 2020-12-30 Blue Sky Vaccines GmbH Influenza virus vector for virotherapy
WO2023138651A1 (en) * 2022-01-19 2023-07-27 Versitech Limited Rationally designed single-round infectious virus and methods of use thereof

Also Published As

Publication number Publication date
TW200621286A (en) 2006-07-01
CN102586199A (en) 2012-07-18

Similar Documents

Publication Publication Date Title
WO2006051069A3 (en) Defective influenza virus particles
CO6470863A2 (en) MUTANTS FGF21 AND USES OF THE SAME
CY1123901T1 (en) PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF
CY1120622T1 (en) METHODS AND COMPOSITIONS FOR INDICATION OF AN IMMUNE RESPONSE TO EGFRVIII
NO20006328D0 (en) Attenuated negative strand virus with altered interferon antagonist activity for use as vaccines and drugs
CO2018003131A2 (en) Oral care compositions comprising a basic amino acid, a combination of zinc ion sources and a thickener system
Lalor et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus
RS52537B (en) Activin-actrii antagonists and uses for treating anemia
BRPI0518568A2 (en) Method for producing a replicative influenza virus particle without the use of helper virus, replicative influenza virus particle, Cell, composition, use of a composition, Method for generating immunological protection against infection of an individual with an influenza virus, , Nucleic acid
EA033386B1 (en) Recombinant immunogenic influenza a virus hemagglutinin stem domain polypeptides and use thereof
BRPI0707543B8 (en) polypeptide composition and use thereof
NO20082149L (en) Canine flu viruses and related compositions and methods of use
Lee et al. Influenza viruses: innate immunity and mRNA vaccines
BR112015025558A2 (en) mouthwash compositions containing silsesquioxane polyiorgan particles
BR0312173A (en) Recombinant cdna molecule, molecule and sequence, vector, process for preparing infectious measles virus particles, immunogenic composition, vaccine composition, and recombinant mononegaviral virus
NO20092254L (en) Powder formulations for valganciclovir
BR112022000490A2 (en) pharmaceutical composition
BRPI0517742A (en) method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual
MX2022012251A (en) Universal influenza vaccine using nucleoside-modifield mrna.
MX2020011586A (en) Synthetic chimeric vaccinia virus.
BR112015032556A2 (en) MODIFIED MATRIX PROTEIN (M) FROM A VESICULAR STOMATITIS VIRUS (VSV); NUCLEOTIDE SEQUENCE ENCODING A MODIFIED MATRIX PROTEIN OF A VESICULAR STOMATITIS VIRUS; RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV); VACCINE; PREPARATION AND BOOST COMBINATION VACCINE; KIT; ISOLATED PEPTIDE; ISOLATED NUCLEOTIDE SEQUENCES; USE OF THE VACCINE; USE OF THE PREPARATION AND BOOST COMBINATION VACCINE; METHOD FOR INDUCING AN IMMUNE RESPONSE IN AN INDIVIDUAL
Stephenson et al. Influenza: current threat from avian influenza
MX2022002766A (en) Influenza virus vaccines and uses thereof.
Kocaağaoğlu et al. An assessment of shear bond strength between ceramic repair systems and different ceramic infrastructures
WO2018013704A1 (en) Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) ,

Free format text: TRANSFERIDO DE: SOLVAY PHARMACEUTICALS B.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) ,

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2281 DE 23/09/2014.